JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target

Benzinga · 09/27 14:46
JMP Securities analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and maintains $80 price target.